FDA Clears AI Tool to Detect Heart Disease Before Symptoms Appear

The FDA has cleared EchoNext, an AI-powered tool that can identify structural heart disease in patients who have no symptoms yet. The clearance marks the first time the agency has approved an AI system specifically designed for early cardiac screening.

EchoNext analyzes echocardiogram images, the ultrasound scans used to examine the heart's structure and function. The tool uses machine learning to detect subtle patterns that can indicate conditions like hypertrophic cardiomyopathy, aortic stenosis, and other structural problems that often go undetected until they cause a serious event like a heart attack or sudden cardiac arrest.

In clinical trials, EchoNext identified abnormalities in patients who had been cleared by standard echocardiogram readings. The tool flagged cases that were later confirmed by specialist review.

"We are catching disease at a stage when we can actually do something about it," said one cardiologist involved in the trials. "That changes outcomes."

Heart disease remains the leading cause of death in the United States. Many patients have no warning signs before a major cardiac event. Early detection tools like EchoNext could allow doctors to start treatment or monitoring before a crisis occurs.

The tool is designed to work alongside human cardiologists, not replace them. EchoNext generates a risk score and highlights areas of concern, which a physician then reviews.

The company behind EchoNext plans to make the tool available to hospitals and cardiology practices later this year. Pricing has not been announced.